드러그인포 약품 상세정보 - 뉴트리플렉스48주사 1000mL

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

667400020[E25110031] [보험코드에 따른 약품기본정보 직접조회]
\0 원/400+600mL/백(2025.01.01)(현재약가)
\18,642 원/400+600mL/백(2024.07.01)(변경전약가)
[상병코드조회]
[질병코드집 다운로드] [우리집건강주치의 바로가기]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

투명한 폴리염화비닐용기 또는 폴리아마이드II(외막)와 폴리프로필렌(내막)으로 이루어진 투명한 플라스틱 용기(V90용기)에 충진된 미황색 (A액 B액 혼합액)의 투명한 액제 [제형정보 확인]

포장·유통단위

1000mL/백

포장·코드단위

약품규격	단위	대표코드	표준코드	비고
1000밀리리터	1 개	8806674000207	8806674000214

주성분코드

317500BIJ [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]

대표코드

8806674000207

보관방법

밀봉용기, 차광보존(15~25℃) 사용기간 : 폴리염화비닐용기(제조일로부터 24개월), V90용기(제조일로부터 18개월)

약리작용

[조회]

효능효과

[적응증 별 검색]

다음 상태시의 아미노산, 당의 보급 : 저단백혈증, 저영양상태, 수술전후

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
○성인 : 총 아미노산으로서 1일 체중 kg 당 1～1.5 g을 최대용량으로 하고 투여속도는 60분간에 총 아미노산으로서 10 g 정도의 농도가 바람직하다.
○투여속도 : 1분간 25～30적으로 점적주사한다.
이 약은 경중심정맥 내 투여를 원칙으로 한다.
소아, 고령자, 단백요구량이 많은 화상환자 등의 경우에는 용량 및 주입속도를 적절히 조절하여 투여하여야 한다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

경고

1) 반드시 의사의 지시에 의하여 사용할 것.
2) 정맥 칼슘 함유 제제와 세프트리악손을 혼합하여 사용할 때, 세프트리악손-칼슘 침전을 일으킬 수 있다. 따라서, 세프트리악손과 이 약을 포함한 정맥 칼슘 함유 제제를 동일한 주입용 기구를 사용하여 동시에 투여해서는 안된다. 연속주입을 위해 동일한 주입선을 사용해야하는 경우, 주입선을 주입 전/후 적절한 용액으로 철저히 씻어낸다.

금기

1) 진행성 간질환, 간성혼수 또는 간성혼수의 우려가 있는 환자
2) 중증 신장애 환자, 고질소혈증 환자
3) 질소이용을 저해하는 대사 장애 환자
4) 소모성 심부전증 환자
5) 폐부종 환자
6) 핍뇨증, 무뇨증 환자
7) 고나트륨혈증과 염소혈증 또는 알칼리증 환자
8) 방실블럭, 중증근무력증 환자
9) 대사성 산증 환자
10) 중증의 혈행역학적 장애 환자(쇽, 중증 심부전, 수분과잉)
11) 저혈당을 제외한 당뇨 합병증 환자
12) 치료받지 않은 요붕증 환자
13) 강심배당체 고용량 치료 중 환자
14) 영유아
15) 수분 과다 공급 환자
16) 고칼륨혈증 환자

신중투여

1) 울혈성 심부전, 중증 신부전, 나트륨 저류로 인한 부종 환자
2) 고칼륨혈증을 수반하지 않는 신부전 환자
3) 간장애, 신장애 환자
4) 췌염, 췌경화증, 췌종양 등 췌장애 환자
5) 중증의 화상 환자
6) 당뇨병 환자
7) 요붕증 환자
8) 탈수증 환자
9) 폐쇄성 요로질환에 의해 요량이 감소된 환자

이상반응

1) 산증 : 다른 고칼로리 수액제 투여 중에 중등한 산증이 발생할 수 있으므로 투여 중에는 관찰을 충분히 하고 증상이 나타나는 경우에는 적절한 처치를 한다.
2) 과민반응 : 드물게 발진 등의 증상이 나타날 수 있으며 이런 경우에는 투여를 중지한다.
3) 소화기계 : 때때로 구역, 구토 등의 증상이 나타날 수 있다.
4) 대량급속투여 : 대량 급속투여 할 경우 산증, 고질소혈증이 나타날 수 있다.
5) 순환기계 : 때때로 흉부불쾌감, 심계항진, 빠른맥(빈맥), 혈압상승 등의 증상이 나타날 수 있다.
6) 가끔 오한, 발열, 혈관통, 두통, 호흡곤란, 호흡정지, 쇽, 기관지경축, 요로경축이 나타날 수 있다.
7) 말초혈관 확장증이 나타날 수 있다.
8) 다음의 대사성 합병증이 나타날 수 있다.
저인산혈증, 알칼리증, 고혈당, 당뇨병, 삼투성이뇨 및 탈수증, 반동성 저혈당, 간효소상승, 비타민결핍 및 비타민 과잉, 전해질불균형, 소아 고암모니아혈증
9) 간부전 및 신부전 환자는 BUN의 상승을 일으킬 수 있다.
10) 간부전 환자는 혈청아미노산 불균형, 대사성 알칼리증, 전신질소혈증, 고암모니아혈증, 지각상실, 혼수 등을 일으킬 수 있다.
11) 불내성 반응이 투여 중, 특히 고속 주입 시 발생할 수 있다.
12) 이 약은 삼투압이 높아 삼투성 이뇨를 일으킬 수 있다.

[주요 이상반응정보]

일반적 주의

1) 당혈증, 전해질, 산염기 평형을 점검한다.
2) 대량투여 시 또는 전해질약을 병용투여할 경우 전해질 평형에 주의한다.
3) 초과량 투여 시 대사성 알칼리증을 일으킬 수 있으므로 초산이온 함유 액제는 주의해서 이용한다.
4) 신장병, 폐질환, 중증 심장병 등 병력이 있는 환자에게는 과량의 체액이 치환되는 것을 피하도록 주의해서 투여한다.
5) 당뇨병 환자에게 투여할 때에는 혈당치를 자주 측정한다.
6) 간세포질환 시, 신경질환의 발생 또는 악화 시에는 투약을 중지한다.
7) 중요한 치료를 하거나 치료를 연장해야 할 경우 혈청검사를 하여 간장병 발생여부를 조사한다.
8) 이 약에는 타이로신이 없으므로 페닐알라닌을 타이로신으로 바꾸는 능력이 저하된 환자에는 고려해야 한다.

상호작용

1) 테트라싸이클린과 병용투여 시 수액아미노산의 단백절약 효과를 감소시킬 수 있다.
2) 칼슘염을 정맥주사하면 마그네슘을 석출시킨다.
3) 인산 및 중탄산염은 침전을 유도할 수 있으므로 이를 포함하는 액을 이 약에 첨가하지 않는다.
4) 칼륨이 포함되어 있으므로 강심배당체의 효과를 감소시킬 수 있다.
5) 칼륨 보존성 이뇨제(아밀로리드, 스피로노락톤, 트리암테렌) 또는 ACE 저해제(에날라프릴, 캅토프릴) 치료를 받고 있는 경우 고칼륨혈증의 발현이 쉬우므로 주의해야 한다.
6) 다른 칼슘 함유 제품과 마찬가지로 세프트리악손과 이 약의 병용투여는 신생아(≤28일)의 혈액에 치명적인 세프트리악손 칼슘 염의 침전 위험이 있다(28일 초과 환자(성인 포함)의 경우 경고 항 참조).

임부에 대한 투여

[임부금기 성분 조회]
임신 중 투여에 대한 안전성이 확립되어 있지 않으므로 임부에 대한 아미노산 수액제 투여는 치료 상의 유익성이 위험성을 상회한다고 판단되는 경우에만 투여한다.

소아에 대한 투여

영유아에는 성분에 대한 요구사항이 다르므로 사용하지 않는다. 신생아, 유아 및 소아에게 경정맥 영양공급을 실시할 때는 소아과 환자들의 특별한 대사적 요구를 만족시키도록 조성된 소아용 아미노산 제제를 사용하는 것이 바람직하다.

고령자에 대한 투여

일반적으로 고령자는 생리기능이 저하되어 있으므로 투여속도를 천천히 하며 감량하는 등 주의한다.

적용상의 주의

1) 이 약은 전해질이 함유되어 있으므로 대량 투여 시 또는 전해질액을 병용투여 시 전해질 평형에 주의한다.
2) 고삼투압 제제이므로 반드시 경중심정맥내로 천천히 투여해야 한다(중심정맥용 주사액에 한함).
3) 한랭기에는 체온 정도로 하여 사용한다.
4) 이 약의 투여 중 패혈증의 위험이 항상 존재하므로 수액제제 조제와 관리는 철저히 무균상태에서 행하고, 주사기구의 멸균에 특별히 주의한다.
5) 잔여액 및 완전히 투명하지 않은 것은 사용하지 말 것이며 용기가 손상되지 않았는지 확인한 후 사용한다.
6) A액과 B액은 사용직전에 혼합하여야 하며, 적주장치가 된 후 즉시 투여한다.
7) 주입 후 남은 액은 버려야 하며 이후 사용 목적으로 보관하지 않는다.
8) 비타민, 미량원소 또는 전해질의 고농축액과 같은 영양보급제와 이약의 적합성이 알려져 있다면 이 약에 첨가할 수 있다.
9) 인슐린을 첨가할 수 있다.
10) 용기에 있는 공기로 인한 공기색전증의 가능성을 피하기 위하여 연속하여 연결해서는 안 된다.

과량투여 및 처치

이 약은 일일 3000 mL(뉴트리플렉스70주사, 아미노플렉스70주사는 2000 mL)를 초과하여 투여하지 않아야 한다. 뉴트리플렉스(아미노플렉스)48주사를 3 mL/분 이상, 뉴트리플렉스(아미노플렉스)32주사를 3.5 mL/분 이상의 속도로 주입하면 현기증 및 구역 뿐 아니라 아미노산 손실을 병행한 삼투성 이뇨를 유도할 수 있다. 주입을 중단하고 중증의 환자에는 복막투석 또는 혈액투석을 한다.

보관 및 취급상의 주의

1) 원포장상태로 상온(15～25℃)에서 차광하여 보관한다.
2) 용기에 표시된 사용기간 경과 후에는 사용하지 않는다.
3) 혼합액은 24～28시간 동안 안정하다.

Related FDA Approved Drug

기준 성분:GLYCINE
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER (GLYCINE)
GLYCINE 1.5% IN PLASTIC CONTAINER (GLYCINE)
기준 성분:GLUCOSE MONOHYDRATE
기준 성분:CALCIUM CHLORIDE
ACETATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
BALANCED SALT (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE)
BSS (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE)
BSS PLUS (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER (CALCIUM CHLORIDE)
CARDIOPLEGIC IN PLASTIC CONTAINER (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
ELLIOTTS B SOLUTION (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE)
ENDOSOL EXTRA (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE)
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE)
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE)
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE)
ISOLYTE E IN PLASTIC CONTAINER (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE)
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE)
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
NAVSTEL (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE)
PLASMA-LYTE R IN PLASTIC CONTAINER (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE)
PLEGISOL IN PLASTIC CONTAINER (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BK 0/0 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE)
RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
TPN ELECTROLYTES IN PLASTIC CONTAINER (CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
성분코드	M224624/엘-이소류신 2.82그램 / M224275/엘-리신염산염 3.41그램 / M230898/엘-글루타민산아르기닌 5.98그램 / M241184/인산이수소나트륨이수화물 3.12그램 / M040439/염화칼슘 0.53그램 / M207074/엘-발린 3.12그램 / M207040/엘-글루타민산 1.47그램 / M044300/포도당일수화물 330적량 / M207047/엘-페닐알라닌 4.21그램 / M207057/엘-아스파라긴산 1.80그램 / M088656/글리신 1.98그램 / M228772/초산마그네슘사수화물 1.23그램 / M230895/엘-류신 3.76그램 / M224258/엘-메티오닌 2.35그램 / M207072/엘-트리프토판 0.68그램 / M207048/엘-프롤린 4.08그램 / M234559/초산나트륨 삼수화물 1.56그램 / M040309/수산화칼륨 1.40그램 / M207071/엘-트레오닌 2.18그램 / M230900/엘-염산히스티딘 2.03그램 / M207050/엘-알라닌 5.82그램 / M207051/엘-세린 3.60그램 / M070004/수산화나트륨 0.23그램 /
주성분코드	317500BIJ [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]
대표코드	8806674000207
BIT 약효분류	비경구영양제(Parenteral Nutritional Products)
ATC 코드	combinations / B05BA10 [코드분류상세설명] [ATC코드예측]
복지부분류코드	325 (단백아미노산제제 )
의약품 바코드정보	내용보기 뉴트리플렉스48주사/E25110031 제품규격:/제품수량:1/제형:개 폼목기준코드:200410468 /대표코드:8806674000207/표준코드:8806674000214 구바코드:-/비고:-
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	667400020[E25110031] [보험코드에 따른 약품기본정보 직접조회] \0 원/400+600mL/백(2025.01.01)(최신약가) \18,642 원/400+600mL/백(2024.07.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	투명한 폴리염화비닐용기 또는 폴리아마이드II(외막)와 폴리프로필렌(내막)으로 이루어진 투명한 플라스틱 용기(V90용기)에 충진된 미황색 (A액 B액 혼합액)의 투명한 액제 [제형정보 확인]
대체관련	대조약
포장·유통단위	1000mL/백
보관방법	밀봉용기, 차광보존(15~25℃) 사용기간 : 폴리염화비닐용기(제조일로부터 24개월), V90용기(제조일로부터 18개월)
동일주성분코드 검색순위	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급
(calcium chloride; )

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Calcium에 대한 독성정보 : 정보보기 L-Glutamic Acid에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Calcium에 대한 Mechanism_Of_Action 정보 Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available. Glycine에 대한 Mechanism_Of_Action 정보 In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS. L-alanine에 대한 Mechanism_Of_Action 정보 L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance. L-arginine에 대한 Mechanism_Of_Action 정보 Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production. L-Histidine에 대한 Mechanism_Of_Action 정보 Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints. L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis. This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells. L-isoleucine에 대한 Mechanism_Of_Action 정보 (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-leucine에 대한 Mechanism_Of_Action 정보 This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-lysine에 대한 Mechanism_Of_Action 정보 Proteins of the herpes simplex virus are rich in L-arginine, and tissue culture studies indicate an enhancing effect on viral replication when the amino acid ratio of L-arginine to L-lysine is high in the tissue culture media. When the ratio of L-lysine to L-arginine is high, viral replication and the cytopathogenicity of herpes simplex virus have been found to be inhibited. L-lysine may facilitate the absorption of calcium from the small intestine. L-methionine에 대한 Mechanism_Of_Action 정보 The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability.
Pharmacology	Glycine에 대한 Pharmacology 정보 Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system. L-alanine에 대한 Pharmacology 정보 Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids. L-arginine에 대한 Pharmacology 정보 Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair. L-Histidine에 대한 Pharmacology 정보 Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing. L-isoleucine에 대한 Pharmacology 정보 They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert. L-leucine에 대한 Pharmacology 정보 An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine L-lysine에 대한 Pharmacology 정보 Insures the adequate absorption of calcium; helps form collagen ( which makes up bone cartilage & connective tissues); aids in the production of antibodies, hormones & enzymes. Recent studies have shown that Lysine may be effective against herpes by improving the balance of nutrients that reduce viral growth. A deficiency may result in tiredness, inability to concentrate, irritability, bloodshot eyes, retarded growth, hair loss, anemia & reproductive problems. L-methionine에 대한 Pharmacology 정보 L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity.
Metabolism	L-Histidine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-isoleucine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-lysine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-methionine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Glutamine SynthetaseMethylenetetrahydrofolate reductase
Absorption	Glycine에 대한 Absorption 정보 Absorbed from the small intestine via an active transport mechanism. L-arginine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism. L-Histidine에 대한 Absorption 정보 Absorbed from the small intestine via an active transport mechanism requiring the presence of sodium. L-isoleucine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium-dependent active-transport process L-lysine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes by an active transport process L-methionine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes by an active transport process.
Biotransformation	Glycine에 대한 Biotransformation 정보 Hepatic L-arginine에 대한 Biotransformation 정보 Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized. L-isoleucine에 대한 Biotransformation 정보 Hepatic L-lysine에 대한 Biotransformation 정보 Hepatic L-methionine에 대한 Biotransformation 정보 Hepatic
Toxicity	Glycine에 대한 Toxicity 정보 ORL-RAT LD₅₀ 7930 mg/kg, SCU-RAT LD₅₀ 5200 mg/kg, IVN-RAT LD₅₀ 2600 mg/kg, ORL-MUS LD₅₀ 4920 mg/kg; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole. L-arginine에 대한 Toxicity 정보 Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses. L-Histidine에 대한 Toxicity 정보 ORL-RAT LD₅₀ > 15000 mg/kg, IPR-RAT LD₅₀ > 8000 mg/kg, ORL-MUS LD₅₀ > 15000 mg/kg, IVN-MUS LD₅₀ > 2000 mg/kg; Mild gastrointestinal side effects. L-isoleucine에 대한 Toxicity 정보 Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs L-lysine에 대한 Toxicity 정보 Not Available L-methionine에 대한 Toxicity 정보 Doses of L-methionine of up to 250 mg daily are generally well tolerated. Higher doses may cause nausea, vomiting and headache. Healthy adults taking 8 grams of L-methionine daily for four days were found to have reduced serum folate levels and leucocytosis. Healthy adults taking 13.9 grams of L-methionine daily for five days were found to have changes in serum pH and potassium and increased urinary calcium excretion. Schizophrenic patients given 10 to 20 grams of L-methionine daily for two weeks developed functional psychoses. Single doses of 8 grams precipitated encephalopathy in patients with cirrhosis.
Drug Interactions	Calcium에 대한 Drug_Interactions 정보 Alendronate Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirChloroquine The antiacid decreases the absorption of chloroquineCiprofloxacin Formation of non-absorbable complexesDapsone Formation of non-absorbable complexesDelavirdine The antiacid decreases the effect of delavirdineDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesFosamprenavir The antiacid decreases the absorption of amprenavirGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesIndinavir The antiacid decreases the absorption of indinavirItraconazole The antacid decreases the effect of the imidazoleKetoconazole The antacid decreases the effect of the imidazoleLevofloxacin Formation of non-absorbable complexesLevothyroxine Calcium decreases absorption of levothyroxineLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesPolystyrene sulfonate Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesMycophenolate mofetil Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexes Glycine에 대한 Drug_Interactions 정보 Not Available L-arginine에 대한 Drug_Interactions 정보 Not Available L-Histidine에 대한 Drug_Interactions 정보 Not Available L-isoleucine에 대한 Drug_Interactions 정보 Not Available L-lysine에 대한 Drug_Interactions 정보 Not Available L-methionine에 대한 Drug_Interactions 정보 Not Available
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	L-methionine에 대한 Food Interaction 정보 Take with food.
Drug Target	[Drug Target]
Description	Calcium에 대한 Description 정보 Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. Glycine에 대한 Description 정보 A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem] L-alanine에 대한 Description 정보 A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem] L-arginine에 대한 Description 정보 An essential amino acid that is physiologically active in the L-form. [PubChem] L-Histidine에 대한 Description 정보 An essential amino acid that is required for the production of histamine. [PubChem] L-isoleucine에 대한 Description 정보 An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem] L-leucine에 대한 Description 정보 An essential branched-chain amino acid important for hemoglobin formation. [PubChem] L-lysine에 대한 Description 정보 L-Lysine (abbreviated as Lys or K)[1] is an 慣-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG.L-Lysine is a base, as are arginine and histidine. The 琯-amino group often participates in hydrogen bonding and as a general base in catalysis. Common posttranslational modifications include methylation of the 琯-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell. L-methionine에 대한 Description 정보 A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. [PubChem]
Drug Category	Glycine에 대한 Drug_Category 정보 Dietary supplementGlycine AgentsMicronutrientNon-Essential Amino Acids L-alanine에 대한 Drug_Category 정보 Dietary supplementMicronutrientNon-Essential Amino Acids L-arginine에 대한 Drug_Category 정보 Conditionally Essential Amino AcidsDietary supplementMicronutrient L-Histidine에 대한 Drug_Category 정보 Conditionally Essential Amino AcidsDietary supplementMicronutrient L-isoleucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-leucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-lysine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-methionine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient
Smiles String Canonical	Calcium에 대한 Smiles_String_canonical 정보 Not Available Glycine에 대한 Smiles_String_canonical 정보 NCC(O)=O L-alanine에 대한 Smiles_String_canonical 정보 CC(N)C(O)=O L-arginine에 대한 Smiles_String_canonical 정보 NC(CCCN=C(N)N)C(O)=O L-Histidine에 대한 Smiles_String_canonical 정보 NC(CC1=CN=CN1)C(O)=O L-isoleucine에 대한 Smiles_String_canonical 정보 CCC(C)C(N)C(O)=O L-leucine에 대한 Smiles_String_canonical 정보 CC(C)CC(N)C(O)=O L-lysine에 대한 Smiles_String_canonical 정보 NCCCCC(N)C(O)=O L-methionine에 대한 Smiles_String_canonical 정보 CSCCC(N)C(O)=O
Smiles String Isomeric	Calcium에 대한 Smiles_String_isomeric 정보 Not Available Glycine에 대한 Smiles_String_isomeric 정보 NCC(O)=O L-alanine에 대한 Smiles_String_isomeric 정보 C[C@H](N)C(O)=O L-arginine에 대한 Smiles_String_isomeric 정보 N[C@@H](CCC\N=C(\N)N)C(O)=O L-Histidine에 대한 Smiles_String_isomeric 정보 N[C@@H](CC1=CN=CN1)C(O)=O L-isoleucine에 대한 Smiles_String_isomeric 정보 CC[C@H](C)[C@H](N)C(O)=O L-leucine에 대한 Smiles_String_isomeric 정보 CC(C)C[C@@H](N)C(O)=O L-lysine에 대한 Smiles_String_isomeric 정보 NCCCC[C@H](N)C(O)=O L-methionine에 대한 Smiles_String_isomeric 정보 CSCC[C@H](N)C(O)=O
InChI Identifier	Calcium에 대한 InChI_Identifier 정보 Not Available Glycine에 대한 InChI_Identifier 정보 InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/f/h4H L-alanine에 대한 InChI_Identifier 정보 InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1/f/h5H L-arginine에 대한 InChI_Identifier 정보 InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1/f/h11H,8-9H2 L-Histidine에 대한 InChI_Identifier 정보 InChI=1/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/f/h9-10H L-isoleucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/f/h8H L-leucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/f/h8H L-lysine에 대한 InChI_Identifier 정보 InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1/f/h9H L-methionine에 대한 InChI_Identifier 정보 InChI=1/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/f/h7H
Chemical IUPAC Name	Calcium에 대한 Chemical_IUPAC_Name 정보 Not Available Glycine에 대한 Chemical_IUPAC_Name 정보 2-aminoacetic acid L-alanine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-aminopropanoic acid L-arginine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid L-Histidine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-3-(3H-imidazol-4-yl)propanoic acid L-isoleucine에 대한 Chemical_IUPAC_Name 정보 (2S,3S)-2-amino-3-methylpentanoic acid L-leucine에 대한 Chemical_IUPAC_Name 정보 2-amino-4-methylpentanoic acid L-lysine에 대한 Chemical_IUPAC_Name 정보 (2S)-2,6-diaminohexanoic acid L-methionine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-4-methylsulfanylbutanoic acid
Drug-Induced Toxicity Related Proteins	LYSINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [바로가기] METHIONINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:NMDA receptor-regulated protein Drug:methionine Toxicity:cerebrovascular disease. [바로가기] Replated Protein:Cystathionine beta-synthase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [바로가기] Replated Protein:Methylenetetrahydrofolate reductase Drug:methionine Toxicity:lipoprotein peroxidation and platelet aggregation. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보